文 献 1）Nagasaki J, Ishino T, Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci 2022; 113: 3303-12. 2）Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 2020; 21: 1346-58. 3）Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1＋ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 2019; 116: 9999-10008. 4）Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol 2019; 16: 356-71. 5）Nagasaki J, Togashi Y, Sugawara T, Itami M, Yamauchi N, Yuda J, et al. The critical role of CD4＋ T cells in PD-1 blockade against MHC-Ⅱ- expressing tumors such as classic Hodgkin lymphoma. Blood Adv 2020; 4: 4069-82. 6）Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, et al. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Cell Rep 2022; 38: 110331. 7）Naoi Y, Morinaga T, Nagasaki J, Ariyasu R, Ueda Y, Yamashita K, et al. CD106 in tumor-specific exhausted CD8＋ T cells mediates immunosuppression by inhibiting TCR signaling. Cancer Res 2024; 84: 2109-22. 8）Baessler A, Vignali DAA. T cell exhaustion. Annu Rev Immunol 2024; 42: 179-206. 9）Crotty S. T follicular helper cell biology: A decade of discovery and diseases. Immunity 2019; 50: 1132-48.10）Manes C, Moreno MG, Cimons J, D'Antonio MA, Brunetti TM, Harbell MG, et al. B cells shape naive CD8＋ T cell programming. J Clin Invest 2025; 135: e190106.11）de Goër de Herve MG, Abdoh M, Jaafoura S, Durali D, Taoufik Y. Follicular CD4 T cells tutor CD8 early memory precursors: An initiatory journey to the frontier of B cell territory. iScience 2019; 20: 100-9.12）Tsuchiya-Kawano Y, Shiraishi Y, Tanaka K, Tachihara M, Saito R, Okamoto T, et al. Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004). Eur J Cancer 2024; 212: 115052.13）Ninomiya T, Kemmotsu N, Mukohara F, Magari M, Miyamoto A, Ueda Y, et al. Myeloid cells induce infiltration and activation of B cells and CD4＋ T follicular helper cells to sensitize brain metastases to combination immunotherapy. Cancer Res 2025; 85: 1082-96.14）Zhou W, Kawashima S, Ishino T, Kawase K, Ueda Y, Yamashita K, et al. Stem-like progenitor and terminally differentiated TFH-like CD4＋ T cell exhaustion in the tumor microenvironment. Cell Rep 2024; 43: 113797.腫瘍微小環境における濾胞性ヘルパー様CD4 陽性T 細胞の本態解明33
元のページ ../index.html#47